Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Policy In Biosimilars, “Breakthrough” And Social Media Under New Management

This article was originally published in The Pink Sheet Daily

Executive Summary

Office of Medical Policy’s leadership gets reshuffled following retirement of the long-time CDER denizen Rachel Sherman.

You may also be interested in...

Chief Scientist At US FDA Is Hinton As Borio Moves To White House

Luciana Borio is detailed to National Security Council; FDA promotes Denise Hinton to acting chief scientist.

FDA Drug Policy Office Director Candidate Getting Four-Month Tryout

OHOP’s Jonathan Jarow will serve 120-day detail as acting director of CDER’s Office of Medical Policy before FDA makes final decision on permanent head of the office.

Former FDA Medical Policy Head Joins Greenleaf, Will Highlight FDA As “Resource”

Rachel Sherman to expand drug capacity at FDA-centered consultancy, following 25 years at agency.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts